Blenrep launch?

When did Blenrep (belantamab mafodotin) launch, and where was it first available?

Blenrep (belantamab mafodotin-blmf) was launched in the U.S. after FDA approval in 2020 for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody. [1]

How was Blenrep positioned at launch (who is it for)?

At launch, Blenrep was indicated for adults with relapsed or refractory multiple myeloma after multiple prior therapies, including:
- an immunomodulatory drug (IMiD)
- a proteasome inhibitor
- an anti-CD38 monoclonal antibody [1]

What happened after launch that affected use or availability?

After launch, Blenrep’s real-world adoption and prescribing were influenced by safety and risk-management issues tied to ocular toxicity (notably corneal events), which drove monitoring and dosing adjustments in practice. [1]

What outcomes are people usually looking for when they search "Blenrep launch"?

Search intent often shifts from the launch date to what the approval covered: the relapsed/refractory population, prior-therapy requirements, and the core safety considerations (especially eye-related effects) that shaped how clinicians used the drug after rollout. [1]

Sources

1. FDA label for BLENREP (belantamab mafodotin-blmf) (highlights/indication and approval context). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761104